Skip to main content
SNWV
NASDAQ Industrial Applications And Services

SANUWAVE Pulls FY2026 Guidance as CMS Reimbursement Uncertainty and Secondary-Market Pressure Mount

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$6.01
Mkt Cap
$51.594M
52W Low
$5.77
52W High
$46.585
52W Position info
4.2% above low
Off High info
87% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

SNWV is trading near its 52-week low of $5.77 (4.2% above the low) on light trading volume (0.3× avg).

Summary

SANUWAVE Health withdrew its FY2026 guidance, citing CMS reimbursement uncertainty and a secondary market for used Ultramist systems that is hurting new system sales. The company plans to challenge CMS's proposed 2027 rule, but clarity is not expected until Q4 2026.


Key Events · Earnings and Guidance · SNWV

  • FY2026 Guidance Withdrawn

    SANUWAVE withdrew its previously issued fiscal year 2026 guidance, citing CMS reimbursement developments and market conditions, and will not provide new guidance until after CMS publishes its final 2027 rule expected in Q4 2026.

  • CMS Reimbursement Headwinds

    Management expressed material disagreement with CMS's proposed 2027 rule for procedure code 97610, which could reduce reimbursement rates, and plans to actively comment during the comment period before the final rule.

  • Secondary Market Cannibalization

    CEO Morgan Frank noted that a significant secondary market for used Ultramist systems has emerged, reducing new system sales and pushing applicator revenue to 75% of total revenue, above the 60-65% target range.

  • Q2 Results: Revenue Slightly Above Guidance, Operating Loss

    Q2 2026 revenue was $9.7 million, down 3% YoY and slightly above the high end of revised guidance, but the company swung to a GAAP operating loss of $0.3 million from a $1.4 million profit a year ago.


Analysis · SNWV · Industrial Applications And Services

SANUWAVE Health withdrew its full-year 2026 guidance, pointing to CMS reimbursement headwinds and a growing secondary market for used Ultramist systems that is cannibalizing new system sales. The company also disclosed its disagreement with CMS's proposed 2027 reimbursement rule for procedure code 97610 and plans to actively comment before the final rule, expected in Q4 2026. This combination of withdrawn guidance, regulatory uncertainty, and a structural shift in system demand materially darkens the near-term outlook for a company already trading near its 52-week low and reporting operating losses.

At the time of this filing, SNWV was trading at $6.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $5.77 to $46.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNWV - Latest Insights

SNWV
Aug 06, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.00
Real-time Price: $6.01 info
Change: +$0.0100 (+0.17%) info
Market Cap: $51.594M info
SNWV
Aug 06, 2026, 4:37 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.00
Real-time Price: $6.01 info
Change: +$0.0100 (+0.17%) info
Market Cap: $51.594M info
SNWV
Jul 13, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.00
Real-time Price: $6.01 info
Change: -$5.99 (-50%) info
Market Cap: $51.594M info
SNWV
Jul 13, 2026, 4:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $11.26
Real-time Price: $6.01 info
Change: -$5.25 (-47%) info
Market Cap: $51.594M info
SNWV
Jun 16, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.99
Real-time Price: $6.01 info
Change: -$5.98 (-50%) info
Market Cap: $51.594M info